• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Hims & Hers Health Inc. (Amendment)

    2/29/24 7:48:47 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email
    SC 13D/A 1 tm247677d1_sc13da.htm SC 13D/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    Hims & Hers Health, Inc.

     

    (Name of Issuer)

     

    Class A Common Stock, par value $0.0001 per share

     

    (Title of Class of Securities)

     

    433000 106

     

    (CUSIP Number)

     

    Tracy Hogan

    Institutional Venture Partners

    3000 Sand Hill Road

    Building 2, Suite 250

    Menlo Park, California 94025

    (650) 854-0132

     

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    February 27, 2024

     

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 2 of 18 Pages

    (1) 

    Names of reporting persons

     

    Institutional Venture Management XV, LLC

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ¨ (b) ¨

    (3)

    SEC use only

     

    (4)

    Source of funds (see instructions):

     

    AF

    (5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
    (6)

    Citizenship or place or organization

     

    Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

    (7) 

    Sole voting power:

     

    0

    (8)

    Shared voting power:

     

    6,222,558 (1)

    (9)

    Sole dispositive power:

     

    0

    (10)

    Shared dispositive power:

     

    6,222,558 (1)

    (11)

    Aggregate amount beneficially owned by each reporting person:

     

    6,222,558 (1)

    (12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
    (13)

    Percent of class represented by amount in Row (11):

     

    3.0% (2)

    (14)

    Type of reporting person (see instructions):

     

    OO

     

    (1)Consists of: (i) 6,176,932 shares of Class A Common Stock held directly by Institutional Venture Partners XV, L.P. (“IVP XV”); (ii) 32,797 shares of Class A Common Stock held directly by Institutional Venture Partners XV Executive Fund, L.P. (“IVP XV EF”); and (iii) 12,829 shares of Class A Common Stock held directly by Institutional Venture Management XV, LLC (“IVM XV”). IVM XV is the general partner of IVP XV and IVP XV EF and may be deemed to share voting and dispositive power over the shares held by IVP XV and IVP XV EF.

     

    (2)Calculations of the percentage of the shares of Class A Common Stock beneficially owned is based on 205,872,690 shares of Class A Common Stock outstanding as of February 23, 2024 as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2024. Represents 2.9% of the total number of outstanding shares of common stock, including 8,377,623 shares of Class V Common Stock (which is entitled to 175 votes per share) and 0.4% of the total voting power of the Issuer.

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 3 of 18 Pages

    (1) 

    Names of reporting persons

     

    Institutional Venture Partners XV, L.P.

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ¨ (b) ¨

    (3)

    SEC use only

     

    (4)

    Source of funds (see instructions):

     

    WC

    (5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
    (6)

    Citizenship or place or organization

     

    Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

    (7) 

    Sole voting power:

     

    0

    (8)

    Shared voting power:

     

    6,176,932 (1)

    (9)

    Sole dispositive power:

     

    0

    (10)

    Shared dispositive power:

     

    6,176,932 (1)

    (11)

    Aggregate amount beneficially owned by each reporting person:

     

    6,176,932 (1)

    (12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
    (13)

    Percent of class represented by amount in Row (11):

     

    3.0% (2)

    (14)

    Type of reporting person (see instructions):

     

    PN

     

    (1)Consists of 6,176,932 shares of Class A Common Stock held directly by IVP XV.

     

    (2)Calculations of the percentage of the shares of Class A Common Stock beneficially owned is based on 205,872,690 shares of Class A Common Stock outstanding as of February 23, 2024 as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2024. Represents 2.9% of the total number of outstanding shares of common stock, including 8,377,623 shares of Class V Common Stock (which is entitled to 175 votes per share) and 0.4% of the total voting power of the Issuer.

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 4 of 18 Pages

    (1) 

    Names of reporting persons

     

    Institutional Venture Partners Executive Fund XV, L.P.

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ¨ (b) ¨

    (3)

    SEC use only

     

    (4)

    Source of funds (see instructions):

     

    WC

    (5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
    (6)

    Citizenship or place or organization

     

    Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

    (7) 

    Sole voting power:

     

    0

    (8)

    Shared voting power:

     

    32,797 (1)

    (9)

    Sole dispositive power:

     

    0

    (10)

    Shared dispositive power:

     

    32,797 (1)

    (11)

    Aggregate amount beneficially owned by each reporting person:

     

    32,797 (1)

    (12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
    (13)

    Percent of class represented by amount in Row (11):

     

    0.0% (2)

    (14)

    Type of reporting person (see instructions):

     

    PN

     

    (1)Consists of 32,797 shares of Class A Common Stock held directly by IVP XV EF.

     

    (2)Calculations of the percentage of the shares of Class A Common Stock beneficially owned is based on 205,872,690 shares of Class A Common Stock outstanding as of February 23, 2024 as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2024. Represents 0.0% of the total number of outstanding shares of common stock, including 8,377,623 shares of Class V Common Stock (which is entitled to 175 votes per share) and 0.0% of the total voting power of the Issuer.

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 5 of 18 Pages

    (1) 

    Names of reporting persons

     

    Institutional Venture Management XVI, LLC

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ¨ (b) ¨

    (3)

    SEC use only

     

    (4)

    Source of funds (see instructions):

     

    AF

    (5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
    (6)

    Citizenship or place or organization

     

    Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

    (7) 

    Sole voting power:

     

    0

    (8)

    Shared voting power:

     

    6,222,570 (1)

    (9)

    Sole dispositive power:

     

    0

    (10)

    Shared dispositive power:

     

    6,222,570 (1)

    (11)

    Aggregate amount beneficially owned by each reporting person:

     

    6,222,570 (1)

    (12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
    (13)

    Percent of class represented by amount in Row (11):

     

    3.0% (2)

    (14)

    Type of reporting person (see instructions):

     

    OO

     

    (1)Consists of (i) 6,209,740 shares of Class A Common Stock held directly by Institutional Venture Partners XVI, L.P. (“IVP XVI”); and (ii) 12,830 shares of Class A Common Stock held directly by Institutional Venture Management XVI, LLC (“IVM XVI”). IVM XVI is the general partner of IVP XVI and may be deemed to share voting and dispositive power over the shares held by IVP XVI.

     

    (2)Calculations of the percentage of the shares of Class A Common Stock beneficially owned is based on 205,872,690 shares of Class A Common Stock outstanding as of February 23, 2024 as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2024. Represents 2.9% of the total number of outstanding shares of common stock, including 8,377,623 shares of Class V Common Stock (which is entitled to 175 votes per share) and 0.4% of the total voting power of the Issuer.

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 6 of 18 Pages

    (1) 

    Names of reporting persons

     

    Institutional Venture Partners XVI, L.P.

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ¨ (b) ¨

    (3)

    SEC use only

     

    (4)

    Source of funds (see instructions):

     

    WC

    (5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
    (6)

    Citizenship or place or organization

     

    Delaware

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

    (7) 

    Sole voting power:

     

    0

    (8)

    Shared voting power:

     

    6,209,740 (1)

    (9)

    Sole dispositive power:

     

    0

    (10)

    Shared dispositive power:

     

    6,209,740 (1)

    (11)

    Aggregate amount beneficially owned by each reporting person:

     

    6,209,740 (1)

    (12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
    (13)

    Percent of class represented by amount in Row (11):

     

    3.0% (2)

    (14)

    Type of reporting person (see instructions):

     

    PN

     

    (1)Consists of 6,209,740 shares of Class A Common Stock held directly by IVP XVI.

     

    (2)Calculations of the percentage of the shares of Class A Common Stock beneficially owned is based on 205,872,690 shares of Class A Common Stock outstanding as of February 23, 2024 as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2024. Represents 2.9% of the total number of outstanding shares of common stock, including 8,377,623 shares of Class V Common Stock (which is entitled to 175 votes per share) and 0.4% of the total voting power of the Issuer.

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 7 of 18 Pages

    (1) 

    Names of reporting persons

     

    Todd C. Chaffee

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ¨ (b) ¨

    (3)

    SEC use only

     

    (4)

    Source of funds (see instructions):

     

    AF

    (5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
    (6)

    Citizenship or place or organization

     

    United States

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

    (7) 

    Sole voting power:

     

    105,923

    (8)

    Shared voting power:

     

    12,445,128 (1)

    (9)

    Sole dispositive power:

     

    105,923

    (10)

    Shared dispositive power:

     

    12,445,128 (1)

    (11)

    Aggregate amount beneficially owned by each reporting person:

     

    12,551,051 (1)

    (12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
    (13)

    Percent of class represented by amount in Row (11):

     

    6.1% (2)

    (14)

    Type of reporting person (see instructions):

     

    IN

     

    (1)Includes (i) 6,176,932 shares of Class A Common Stock beneficially owned by IVP XV; (ii) 32,797 shares of Class A Common Stock beneficially owned by IVP XV EF; (iii) 12,829 shares of Class A Common Stock held directly by IVM XV; (iv) 6,209,740 shares of Class A Common Stock held directly by IVP XVI; and 12,830 shares of Class A Common Stock held directly by IVM XVI. IVM XV is the general partner of IVP XV and IVP XV EF and may be deemed to share voting and dispositive power over the shares held by IVP XV and IVP XV EF, and IVM XVI is the general partner of IVP XVI and may be deemed to share voting and dispositive power over the shares held by IVP XVI. Chaffee, Fogelsong, Harrick, Miller, Phelps, Liaw, Dash and Maltz are the managing members of IVM XV and IVM XVI and may be deemed to share voting and dispositive power over the shares held by IVP XV, IVP XV EF, IVM XV, IVP XVI and IVM XI.

     

    (2)Calculations of the percentage of the shares of Class A Common Stock beneficially owned is based on 205,872,690 shares of Class A Common Stock outstanding as of February 23, 2024 as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2024. Represents 5.9% of the total number of outstanding shares of common stock, including 8,377,623 shares of Class V Common Stock (which is entitled to 175 votes per share) and 0.8% of the total voting power of the Issuer.

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 8 of 18 Pages

    (1) 

    Names of reporting persons

     

    Norman A. Fogelsong

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ¨ (b) ¨

    (3)

    SEC use only

     

    (4)

    Source of funds (see instructions):

     

    AF

    (5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
    (6)

    Citizenship or place or organization

     

    United States

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

    (7) 

    Sole voting power:

     

    83,829

    (8)

    Shared voting power:

     

    12,445,128 (1)

    (9)

    Sole dispositive power:

     

    83,829

    (10)

    Shared dispositive power:

     

    12,445,128 (1)

    (11)

    Aggregate amount beneficially owned by each reporting person:

     

    12,528,957 (1)

    (12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
    (13)

    Percent of class represented by amount in Row (11):

     

    6.1% (2)

    (14)

    Type of reporting person (see instructions):

     

    IN

     

    (1)Includes (i) 6,176,932 shares of Class A Common Stock beneficially owned by IVP XV; (ii) 32,797 shares of Class A Common Stock beneficially owned by IVP XV EF; (iii) 12,829 shares of Class A Common Stock held directly by IVM XV; (iv) 6,209,740 shares of Class A Common Stock held directly by IVP XVI; and 12,830 shares of Class A Common Stock held directly by IVM XVI. IVM XV is the general partner of IVP XV and IVP XV EF and may be deemed to share voting and dispositive power over the shares held by IVP XV and IVP XV EF, and IVM XVI is the general partner of IVP XVI and may be deemed to share voting and dispositive power over the shares held by IVP XVI. Chaffee, Fogelsong, Harrick, Miller, Phelps, Liaw, Dash and Maltz are the managing members of IVM XV and IVM XVI and may be deemed to share voting and dispositive power over the shares held by IVP XV, IVP XV EF, IVM XV, IVP XVI and IVM XI.

     

    (2)Calculations of the percentage of the shares of Class A Common Stock beneficially owned is based on 205,872,690 shares of Class A Common Stock outstanding as of February 23, 2024 as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2024. Represents 5.8% of the total number of outstanding shares of common stock, including 8,377,623 shares of Class V Common Stock (which is entitled to 175 votes per share) and 0.7% of the total voting power of the Issuer.

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 9 of 18 Pages

    (1) 

    Names of reporting persons

     

    Stephen J. Harrick

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ¨ (b) ¨

    (3)

    SEC use only

     

    (4)

    Source of funds (see instructions):

     

    AF

    (5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
    (6)

    Citizenship or place or organization

     

    United States

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

    (7) 

    Sole voting power:

     

    201,324

    (8)

    Shared voting power:

     

    12,445,128 (1)

    (9)

    Sole dispositive power:

     

    201,324

    (10)

    Shared dispositive power:

     

    12,445,128 (1)

    (11)

    Aggregate amount beneficially owned by each reporting person:

     

    12,646,452 (1)

    (12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
    (13)

    Percent of class represented by amount in Row (11):

     

    6.1% (2)

    (14)

    Type of reporting person (see instructions):

     

    IN

     

    (1)Includes (i) 6,176,932 shares of Class A Common Stock beneficially owned by IVP XV; (ii) 32,797 shares of Class A Common Stock beneficially owned by IVP XV EF; (iii) 12,829 shares of Class A Common Stock held directly by IVM XV; (iv) 6,209,740 shares of Class A Common Stock held directly by IVP XVI; and 12,830 shares of Class A Common Stock held directly by IVM XVI. IVM XV is the general partner of IVP XV and IVP XV EF and may be deemed to share voting and dispositive power over the shares held by IVP XV and IVP XV EF, and IVM XVI is the general partner of IVP XVI and may be deemed to share voting and dispositive power over the shares held by IVP XVI. Chaffee, Fogelsong, Harrick, Miller, Phelps, Liaw, Dash and Maltz are the managing members of IVM XV and IVM XVI and may be deemed to share voting and dispositive power over the shares held by IVP XV, IVP XV EF, IVM XV, IVP XVI and IVM XI.

     

    (2)Calculations of the percentage of the shares of Class A Common Stock beneficially owned is based on 205,872,690 shares of Class A Common Stock outstanding as of February 23, 2024 as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2024. Represents 5.9% of the total number of outstanding shares of common stock, including 8,377,623 shares of Class V Common Stock (which is entitled to 175 votes per share) and 0.8% of the total voting power of the Issuer.

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 10 of 18 Pages

    (1) 

    Names of reporting persons

     

    J. Sanford Miller

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ¨ (b) ¨

    (3)

    SEC use only

     

    (4)

    Source of funds (see instructions):

     

    AF

    (5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
    (6)

    Citizenship or place or organization

     

    United States

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

    (7) 

    Sole voting power:

     

    116,975

    (8)

    Shared voting power:

     

    12,445,128 (1)

    (9)

    Sole dispositive power:

     

    116,975

    (10)

    Shared dispositive power:

     

    12,445,128 (1)

    (11)

    Aggregate amount beneficially owned by each reporting person:

     

    12,562,103 (1) 

    (12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
    (13)

    Percent of class represented by amount in Row (11):

     

    6.1% (2)

    (14)

    Type of reporting person (see instructions):

     

    IN

     

    (1)Includes (i) 6,176,932 shares of Class A Common Stock beneficially owned by IVP XV; (ii) 32,797 shares of Class A Common Stock beneficially owned by IVP XV EF; (iii) 12,829 shares of Class A Common Stock held directly by IVM XV; (iv) 6,209,740 shares of Class A Common Stock held directly by IVP XVI; and 12,830 shares of Class A Common Stock held directly by IVM XVI. IVM XV is the general partner of IVP XV and IVP XV EF and may be deemed to share voting and dispositive power over the shares held by IVP XV and IVP XV EF, and IVM XVI is the general partner of IVP XVI and may be deemed to share voting and dispositive power over the shares held by IVP XVI. Chaffee, Fogelsong, Harrick, Miller, Phelps, Liaw, Dash and Maltz are the managing members of IVM XV and IVM XVI and may be deemed to share voting and dispositive power over the shares held by IVP XV, IVP XV EF, IVM XV, IVP XVI and IVM XI.

     

    (2)Calculations of the percentage of the shares of Class A Common Stock beneficially owned is based on 205,872,690 shares of Class A Common Stock outstanding as of February 23, 2024 as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2024. Represents 5.9% of the total number of outstanding shares of common stock, including 8,377,623 shares of Class V Common Stock (which is entitled to 175 votes per share) and 0.8% of the total voting power of the Issuer.

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 11 of 18 Pages

    (1) 

    Names of reporting persons

     

    Dennis B. Phelps

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ¨ (b) ¨

    (3)

    SEC use only

     

    (4)

    Source of funds (see instructions):

     

    AF

    (5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
    (6)

    Citizenship or place or organization

     

    United States

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

    (7) 

    Sole voting power:

     

    201,324

    (8)

    Shared voting power:

     

    12,445,128 (1)

    (9)

    Sole dispositive power:

     

    201,324

    (10)

    Shared dispositive power:

     

    12,445,128 (1)

    (11)

    Aggregate amount beneficially owned by each reporting person:

     

    12,646,452 (1)

    (12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
    (13)

    Percent of class represented by amount in Row (11):

     

    6.1% (2)

    (14)

    Type of reporting person (see instructions):

     

    IN

     

    (1)Includes (i) 6,176,932 shares of Class A Common Stock beneficially owned by IVP XV; (ii) 32,797 shares of Class A Common Stock beneficially owned by IVP XV EF; (iii) 12,829 shares of Class A Common Stock held directly by IVM XV; (iv) 6,209,740 shares of Class A Common Stock held directly by IVP XVI; and 12,830 shares of Class A Common Stock held directly by IVM XVI. IVM XV is the general partner of IVP XV and IVP XV EF and may be deemed to share voting and dispositive power over the shares held by IVP XV and IVP XV EF, and IVM XVI is the general partner of IVP XVI and may be deemed to share voting and dispositive power over the shares held by IVP XVI. Chaffee, Fogelsong, Harrick, Miller, Phelps, Liaw, Dash and Maltz are the managing members of IVM XV and IVM XVI and may be deemed to share voting and dispositive power over the shares held by IVP XV, IVP XV EF, IVM XV, IVP XVI and IVM XI.

     

    (2)Calculations of the percentage of the shares of Class A Common Stock beneficially owned is based on 205,872,690 shares of Class A Common Stock outstanding as of February 23, 2024 as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2024. Represents 5.9% of the total number of outstanding shares of common stock, including 8,377,623 shares of Class V Common Stock (which is entitled to 175 votes per share) and 0.8% of the total voting power of the Issuer.

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 12 of 18 Pages

    (1) 

    Names of reporting persons

     

    Eric Liaw

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ¨ (b) ¨

    (3)

    SEC use only

     

    (4)

    Source of funds (see instructions):

     

    AF

    (5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
    (6)

    Citizenship or place or organization

     

    United States

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

    (7) 

    Sole voting power:

     

    81,394

    (8)

    Shared voting power:

     

    12,445,128 (1)

    (9)

    Sole dispositive power:

     

    81,394

    (10)

    Shared dispositive power:

     

    12,445,128 (1)

    (11)

    Aggregate amount beneficially owned by each reporting person:

     

    12,526,522 (1)

    (12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
    (13)

    Percent of class represented by amount in Row (11):

     

    6.1% (2)

    (14)

    Type of reporting person (see instructions):

     

    IN

     

    (1)Includes (i) 6,176,932 shares of Class A Common Stock beneficially owned by IVP XV; (ii) 32,797 shares of Class A Common Stock beneficially owned by IVP XV EF; (iii) 12,829 shares of Class A Common Stock held directly by IVM XV; (iv) 6,209,740 shares of Class A Common Stock held directly by IVP XVI; and 12,830 shares of Class A Common Stock held directly by IVM XVI. IVM XV is the general partner of IVP XV and IVP XV EF and may be deemed to share voting and dispositive power over the shares held by IVP XV and IVP XV EF, and IVM XVI is the general partner of IVP XVI and may be deemed to share voting and dispositive power over the shares held by IVP XVI. Chaffee, Fogelsong, Harrick, Miller, Phelps, Liaw, Dash and Maltz are the managing members of IVM XV and IVM XVI and may be deemed to share voting and dispositive power over the shares held by IVP XV, IVP XV EF, IVM XV, IVP XVI and IVM XI.

     

    (2)Calculations of the percentage of the shares of Class A Common Stock beneficially owned is based on 205,872,690 shares of Class A Common Stock outstanding as of February 23, 2024 as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2024. Represents 5.8% of the total number of outstanding shares of common stock, including 8,377,623 shares of Class V Common Stock (which is entitled to 175 votes per share) and 0.7% of the total voting power of the Issuer.

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 13 of 18 Pages

    (1) 

    Names of reporting persons

     

    Somesh Dash

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ¨ (b) ¨

    (3)

    SEC use only

     

    (4)

    Source of funds (see instructions):

     

    AF

    (5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
    (6)

    Citizenship or place or organization

     

    United States

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

    (7) 

    Sole voting power:

     

    81,394

    (8)

    Shared voting power:

     

    12,445,128 (1)

    (9)

    Sole dispositive power:

     

    81,394

    (10)

    Shared dispositive power:

     

    12,445,128 (1)

    (11)

    Aggregate amount beneficially owned by each reporting person:

     

    12,526,522 (1)

    (12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
    (13)

    Percent of class represented by amount in Row (11):

     

    6.1% (2)

    (14)

    Type of reporting person (see instructions):

     

    IN

     

    (1)Includes (i) 6,176,932 shares of Class A Common Stock beneficially owned by IVP XV; (ii) 32,797 shares of Class A Common Stock beneficially owned by IVP XV EF; (iii) 12,829 shares of Class A Common Stock held directly by IVM XV; (iv) 6,209,740 shares of Class A Common Stock held directly by IVP XVI; and 12,830 shares of Class A Common Stock held directly by IVM XVI. IVM XV is the general partner of IVP XV and IVP XV EF and may be deemed to share voting and dispositive power over the shares held by IVP XV and IVP XV EF, and IVM XVI is the general partner of IVP XVI and may be deemed to share voting and dispositive power over the shares held by IVP XVI. Chaffee, Fogelsong, Harrick, Miller, Phelps, Liaw, Dash and Maltz are the managing members of IVM XV and IVM XVI and may be deemed to share voting and dispositive power over the shares held by IVP XV, IVP XV EF, IVM XV, IVP XVI and IVM XI.

     

    (2)Calculations of the percentage of the shares of Class A Common Stock beneficially owned is based on 205,872,690 shares of Class A Common Stock outstanding as of February 23, 2024 as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2024. Represents 5.8% of the total number of outstanding shares of common stock, including 8,377,623 shares of Class V Common Stock (which is entitled to 175 votes per share) and 0.7% of the total voting power of the Issuer.

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 14 of 18 Pages

    (1) 

    Names of reporting persons

     

    Jules A. Maltz

    (2)

    Check the appropriate box if a member of a group (see instructions)

     

    (a) ¨ (b) ¨

    (3)

    SEC use only

     

    (4)

    Source of funds (see instructions):

     

    AF

    (5) Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ¨
    (6)

    Citizenship or place or organization

     

    United States

    Number of

    shares

    beneficially

    owned by

    each

    reporting

    person

    with:

    (7) 

    Sole voting power:

     

    344,738

    (8)

    Shared voting power:

     

    12,445,128 (1)

    (9)

    Sole dispositive power:

     

    344,738

    (10)

    Shared dispositive power:

     

    12,445,128 (1)

    (11)

    Aggregate amount beneficially owned by each reporting person:

     

    12,789,866 (1)

    (12) Check if the aggregate amount in Row (11) excludes certain shares (see instructions) ¨
    (13)

    Percent of class represented by amount in Row (11):

     

    6.2% (2)

    (14)

    Type of reporting person (see instructions):

     

    IN

     

    (1)Includes (i) 6,176,932 shares of Class A Common Stock beneficially owned by IVP XV; (ii) 32,797 shares of Class A Common Stock beneficially owned by IVP XV EF; (iii) 12,829 shares of Class A Common Stock held directly by IVM XV; (iv) 6,209,740 shares of Class A Common Stock held directly by IVP XVI; and 12,830 shares of Class A Common Stock held directly by IVM XVI. IVM XV is the general partner of IVP XV and IVP XV EF and may be deemed to share voting and dispositive power over the shares held by IVP XV and IVP XV EF, and IVM XVI is the general partner of IVP XVI and may be deemed to share voting and dispositive power over the shares held by IVP XVI. Chaffee, Fogelsong, Harrick, Miller, Phelps, Liaw, Dash and Maltz are the managing members of IVM XV and IVM XVI and may be deemed to share voting and dispositive power over the shares held by IVP XV, IVP XV EF, IVM XV, IVP XVI and IVM XI.

     

    (2)Calculations of the percentage of the shares of Class A Common Stock beneficially owned is based on 205,872,690 shares of Class A Common Stock outstanding as of February 23, 2024 as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2024. Represents 6.0% of the total number of outstanding shares of common stock, including 8,377,623 shares of Class V Common Stock (which is entitled to 175 votes per share) and 0.8% of the total voting power of the Issuer.

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 15 of 18 Pages

     

    Explanatory Note: This Amendment No. 2 (the “Amendment”), which amends the Schedule 13D filed with the SEC on February 1, 2021 and amended on March 6, 2023 (the “Original Schedule 13D”), is being filed on behalf of Institutional Venture Management XV, LLC (“IVM XV”), Institutional Venture Partners XV, L.P. (“IVP XV”), Institutional Venture Partners XV Executive Fund, L.P. (“IVP XV EF”), Institutional Venture Management XVI, LLC (“IVM XVI”), Institutional Venture Partners XVI, L.P. (“IVP XVI”), Todd C. Chaffee (“Chafee”), Norman A. Fogelsong (“Fogelsong”), Stephen J. Harrick (“Harrick”), J. Sanford Miller (“Miller”), Dennis B. Phelps (“Phelps”), Eric Liaw (“Liaw”), Somesh Dash (“Dash”) and Jules A. Maltz (“Maltz,” and together with IVM XV, IVP XV, IVP XV EF, IVM XVI, IVP XVI, Chafee, Fogelsong, Harrick, Miller, Phelps, Liaw and Dash, collectively the “Reporting Persons”) in respect of the Class A Common Stock, par value $0.0001 per share (“Class A Common Stock”) of Hims & Hers Health, Inc., a Delaware corporation (the “Issuer”). This Amendment is being filed by the Reporting Persons to report the distributions in kind of Class A Common Stock on February 27, 2024. Accordingly, the number of securities beneficially owned by the Reporting Persons has decreased as described in Items 4 and 5 below.

     

    Items 4 and 5 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

     

    Item 4.Purpose of Transaction

     

    Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraphs at the end of Item 4:

     

    On February 27, 2024, IVP XV made a pro rata in-kind distribution for no additional consideration of an aggregate of 1,492,062 shares of Class A Common Stock to its general partner and limited partners. Of the shares distributed by IVP XV, IVM XV received 322,285 shares.

     

    On February 27, 2024, IVP XV EF made a pro rata in-kind distribution for no additional consideration of an aggregate of 7,938 shares of Class A Common Stock to its limited partners.

     

    On February 27, 2024, IVP XVI made a pro rata in-kind distribution for no additional consideration of an aggregate of 1,500,000 shares of Class A Common Stock to its general partner and limited partners. Of the shares distributed by IVP XVI, Institutional Venture Partners Executive Fund XVI, LLC (“IVP XVI EF”) and IVM XVI received 19,908 and 398,148 shares, respectively.

     

    On February 27, 2024, IVM XV made a pro rata in-kind distribution for no additional consideration of an aggregate of 322,285 shares of Class A Common Stock to its members. Of the shares distributed by IVM XV, Chaffee, Dash, Fogelson, Harrick, Miller, Phelps, Liaw and Maltz received 52,203; 13,050; 26,100; 52,203; 40,456; 52,203; 13,050 and 52,203 shares, respectively.

     

    On February 27, 2024, IVM XVI made a pro rata in-kind distribution for no additional consideration of an aggregate of 398,148 shares of Class A Common Stock to its members. Of the shares distributed by IVM XVI, Chaffee, Dash, Fogelson, Harrick, Miller, Phelps, Liaw and Maltz received 53,720; 40,292; 26,860; 53,720; 45,661; 53,720; 40,292; and 53,720 shares respectively.

     

    On February 27, 2024, IVP XVI EF made a pro rata in-kind distribution for no additional consideration of an aggregate of 19,908 shares of Class A Common Stock to its members.

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 16 of 18 Pages

     

    Item 5.Interest in Securities of the Issuer

     

    Item 5 of the Original Schedule 13D is hereby amended and restated in its entirety as follows:

     

    The information contained in Item 3 of this Schedule 13D is incorporated by reference herein.

     

    (a), (b)The responses of the Reporting Persons with respect to Rows 7 through 13 of their respective cover pages to this Schedule 13D are incorporated herein by reference.

     

    The Reporting Persons’ aggregate percentage of beneficial ownership is approximately 6.6% of the outstanding shares of the Class A Common Stock. Calculations of the percentage of the shares of Class A Common Stock beneficially owned is based on 205,872,690 shares of Class A Common Stock outstanding as of February 23, 2024 as disclosed in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 26, 2024. The shares beneficially owned by the Reporting Persons represent 6.4% of the total number of outstanding shares of common stock, including an additional 8,377,623 shares of Class V Common Stock (which is entitled to 175 votes per share) and 0.8% of the total voting power of the Issuer.

     

    Each of the Reporting Persons expressly disclaims beneficial ownership of all of the shares of Class A Common Stock included in this Schedule 13D, other than the shares of Class A Common Stock held of record by such Reporting Person, and the filing of this Schedule 13D shall not be construed as an admission that any such person is, for the purposes of sections 13(d) or 13(g) of the Exchange Act of 1934, as amended, the beneficial owner of any securities covered by this Schedule 13D.

     

    (c)Except as set forth in this Schedule 13D, none of the Reporting Persons nor, to the best of its knowledge, any of the Listed Persons has engaged in any transaction with respect to the Class A Common Stock during the sixty days prior to the date of filing of this Schedule 13D.

     

    (d)To the best knowledge of the Reporting Persons, no one other than the Reporting Persons, or the partners, members, affiliates or shareholders of the Reporting Persons, is known to have the right to receive, or the power to direct the receipt of, dividends from, or proceeds from the sale of, the shares of Class A Common Stock reported herein as beneficially owned by the Reporting Persons.

     

    (e)Not applicable.

     

    Item 7.Material to Be Filed as Exhibits

     

    AJoint Filing Agreement, dated February 1, 2021 (incorporated by reference to the Original Schedule 13D, filed on February 1, 2021).

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 17 of 18 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:    February 29, 2024

     

    INSTITUTIONAL VENTURE PARTNERS XV, L.P.  
       
    By: Institutional Venture Management XV, LLC  
    Its: General Partner  
       
    By: /s/ Tracy Hogan  
      Tracy Hogan, Attorney-in-Fact  
       
    INSTITUTIONAL VENTURE PARTNERS EXECUTIVE FUND XV, L.P.  
       
    By: Institutional Venture Management XV, LLC  
    Its: General Partner  
       
    By: /s/ Tracy Hogan  
      Tracy Hogan, Attorney-in-Fact  
       
    INSTITUTIONAL VENTURE MANAGEMENT XV, LLC  
       
    By: /s/ Tracy Hogan  
      Tracy Hogan, Attorney-in-Fact  
       
    INSTITUTIONAL VENTURE PARTNERS XVI, L.P.  
       
    By: Institutional Venture Management XVI, LLC  
    Its: General Partner  
       
    By: /s/ Tracy Hogan  
      Tracy Hogan, Attorney-in-Fact  
       
    INSTITUTIONAL VENTURE MANAGEMENT XVI, LLC  
       
    By: /s/ Tracy Hogan  
      Tracy Hogan, Attorney-in-Fact  
       
      /s/ Tracy Hogan  
    Tracy Hogan, Attorney-in-Fact for Todd C. Chaffee  
       
      /s/ Tracy Hogan  
    Tracy Hogan, Attorney-in-Fact for Norman A. Fogelsong  

     

     

     

     

    CUSIP No. 433000 106 Schedule 13D Page 18 of 18 Pages

     

      /s/ Tracy Hogan  
    Tracy Hogan, Attorney-in-Fact for Stephen J. Harrick  
       
      /s/ Tracy Hogan  
    Tracy Hogan, Attorney-in-Fact for J. Sanford Miller  
       
      /s/ Tracy Hogan  
    Tracy Hogan, Attorney-in-Fact for Dennis B. Phelps  
       
      /s/ Tracy Hogan  
    Tracy Hogan, Attorney-in-Fact for Eric Liaw  
       
      /s/ Tracy Hogan  
    Tracy Hogan, Attorney-in-Fact for Somesh Dash  
       
      /s/ Tracy Hogan  
    Tracy Hogan, Attorney-in-Fact for Jules A. Maltz  

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement: provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact
    constitute Federal criminal violations (See 18 U.S.C. 1001)

     

     

     

    Get the next $HIMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    4/29/2025$30.00Buy → Hold
    TD Cowen
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    1/7/2025$35.00Buy
    BTIG Research
    12/17/2024$42.00Overweight
    Morgan Stanley
    11/14/2024Buy → Underperform
    BofA Securities
    8/22/2024$24.00Buy
    Needham
    8/9/2024Outperform → In-line
    Imperial Capital
    More analyst ratings

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      11/14/24 4:57:45 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/22/24 4:16:26 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Financials

    Live finance-specific insights

    See more
    • Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results

      Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million Introduces 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2025, in a shareholder letter that is posted at investors.him

      5/5/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025

      Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 5, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's management team

      4/14/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      Revenue of $1.5 billion, up 69% year-over-year in 2024 Net income of $126 million; Adjusted EBITDA of $177 million in 2024 Subscribers grew to 2.2 million, up 45% year-over-year in 2024 Provides Q1 and full year 2025 guidance, with full year 2025 revenue in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $270 million to $320 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2024 in a shareholder letter that is posted at investors.hims.com. "2024 was a fantastic year at Hims and Hers as we con

      2/24/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

      Proceeds intended to support Hims & Hers' global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising demand for high-quality, personalized care Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased

      5/8/25 10:25:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

      Proceeds intended to support Hims & Hers' global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising demand for high-quality, personalized care Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Him

      5/8/25 7:57:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

      Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

      5/8/25 6:50:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer Boughton Soleil sold $97,695 worth of shares (3,236 units at $30.19), decreasing direct ownership by 2% to 159,662 units (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      4/30/25 6:01:31 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Chief Executive Officer Dudum Andrew exercised 91,667 shares at a strike of $2.43 and sold $3,077,070 worth of shares (91,667 units at $33.57) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      4/30/25 6:01:20 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Chief Operating Officer Baird Melissa exercised 33,333 shares at a strike of $1.97 and sold $859,256 worth of shares (33,333 units at $25.78) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      4/23/25 4:21:49 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    SEC Filings

    See more

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 10-Q filed by Hims & Hers Health Inc.

      10-Q - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/5/25 4:17:34 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/5/25 4:10:43 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • SEC Form DEFA14A filed by Hims & Hers Health Inc.

      DEFA14A - Hims & Hers Health, Inc. (0001773751) (Filer)

      4/25/25 4:20:57 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/12/24 3:52:47 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/4/24 1:33:02 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/4/24 12:09:24 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health downgraded by TD Cowen with a new price target

      TD Cowen downgraded Hims & Hers Health from Buy to Hold and set a new price target of $30.00

      4/29/25 8:05:51 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Hims & Hers Health from Overweight to Equal-Weight and set a new price target of $60.00 from $42.00 previously

      2/18/25 7:09:28 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health downgraded by Citigroup with a new price target

      Citigroup downgraded Hims & Hers Health from Neutral to Sell and set a new price target of $25.00 from $24.00 previously

      1/10/25 7:53:16 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

      Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

      5/8/25 6:50:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer

      Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A seasoned executive known for scaling trusted consumer and healthcare logistics businesses, Kabbani will oversee operations as the company expands access to personalized care for millions more individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/ne

      5/5/25 9:01:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Define Ventures Appoints Carolyn Magill as Venture Partner

      The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

      3/11/25 5:30:00 AM ET
      $EVH
      $HIMS
      $LVGO
      Other Consumer Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care